Home > Boards > US Listed > Medical - Drugs > GlaxoSmithKline (GSK)

GSK to skyrocket to $100+ with Ebola Vaccine

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
oscaraft Member Profile
 
Followed By 0
Posts 4
Boards Moderated 0
Alias Born 01/14/15
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 5:28:29 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 5:08:57 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 2:08:05 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 10:30:25 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 8:12:12 AM
GlaxoSmithKline: Phase 3 Study of Zejula Met Trial Objectives Dow Jones News - 7/15/2019 2:43:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/12/2019 1:13:34 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/12/2019 1:04:43 PM
EU Approves With Conditions GlaxoSmithKline's Acquisition of Pfizer's Consumer Health Business Dow Jones News - 7/11/2019 5:02:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/10/2019 12:00:33 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/10/2019 6:17:08 AM
GlaxoSmithKline, Pfizer's HIV Treatment Meets Primary Endpoint in Trial Dow Jones News - 7/10/2019 2:54:00 AM
Fulcrum Therapeutics Sets IPO at 4.5 Million Shares; Sees Pricing at $16-$18 Apiece Dow Jones News - 7/8/2019 7:13:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/3/2019 7:59:46 AM
South Africa Gives Conditional Go-Ahead to GSK-Pfizer JV -Reuters Dow Jones News - 7/2/2019 2:10:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/1/2019 10:46:28 AM
Liquidia Technologies Gets Right to Develop More Products in Revised GlaxoSmithKline Agreement Dow Jones News - 6/26/2019 7:28:00 PM
GSK Offers Concessions on Pfizer JV to Quell EU Antitrust Fears Dow Jones News - 6/20/2019 6:53:00 AM
Morphic Holding Sets IPO at 5 Million Shares; Sees Pricing at $14-$16 Apiece Dow Jones News - 6/14/2019 8:04:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2019 1:32:53 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/7/2019 6:38:58 AM
Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options Business Wire - 6/6/2019 5:15:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2019 6:22:29 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/3/2019 11:12:00 AM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/31/2019 2:05:17 PM
oscaraft   Saturday, 01/17/15 12:41:16 PM
Re: None
Post # of 137 
GSK to skyrocket to $100+ with Ebola Vaccine -

There is very little doubt that GSK will skyrocket to $100 + once the Ebola vaccine comes out at the end of this month. This is an incredible opportunity! $100 - $125 would not be unreasonable in the short term. GSK is definitely a strong buy at the moment and possibly the chance of a lifetime.

Fasten your seat belts folks! A huge run is coming with GSK!

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist